Given these findings, we reasoned that the filamentation process of BCL10 may represent an effective and relatively safe target for the pharmaceutical inhibition of CB-SMOC formation in B cell lymphomas. The gene discussed is BCL10; the disease is B-cell non-Hodgkin lymphoma.